Other Transaction Agreement HR0011269E017
- Not listed
- <p>The U.S. Defense Advanced Research Projects Agency (DARPA) awarded a $371,091.00 Other Transaction Agreement to Sequre DX Inc., a for-profit organization, for the "EXPERIMENTAL OPTIMIZATION AND COMMERCIALIZATION OF GENE EDITOR OFFTARGET ASSAYS" project. The contract is for work to be performed in Boston, MA and has a completion date of September 30, 2021. This contract is not set aside for any specific business type.</p>
- This is a $149,661.75 firm-fixed-price Phase I Small Business Innovation Research (SBIR) contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Biodiscovery LLC, doing business as Daicel Arbor Biosciences, a foreign-owned, for-profit manufacturer. The contract is for the development of a next-generation cell-free prototyping and biomanufacturing platform. Biodiscovery LLC, a subsidiary of the Japanese chemical company Daicel Corporation, specializes in custom molecular...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to B-Mogen Biotechnologies Inc. for the development of "NEXT GENERATION GENOME EDITING TOOLS." The contract is a firm-fixed-price definitive contract with a ceiling value of $149,431.43 and a period of performance ending on April 20, 2018. As an SBIR Phase I award, this contract is focused on the research and development of innovative technologies that...
- This is a Firm Fixed Price, Definitive Contract awarded by the Defense Advanced Research Projects Agency (DARPA) under the SBIR Program Phase II to De Novo DNA, a self-certified small disadvantaged business. The contract is for the development of "HIGHLY SCALABLE MULTIPLEXED CRISPR TECHNOLOGIES FOR MEDICAL, INDUSTRIAL, AND AGRICULTURAL" and has a ceiling value of $1,959,347.00. The contract was awarded on September 18, 2018 and is set to be completed by November 17, 2021. This contract...
- <p>This is a $149,998.88 Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to De Novo DNA, a self-certified small disadvantaged business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for "HIGHLY SCALABLE MULTIPLEXED CRISPR APPLICATIONS USING ADVANCED PART TOOLBOXES AND CIRCUITS" and has an ultimate completion date of October 7, 2018. The contract is designated as a Total Small Business set-aside.</p>
- This is a Cost Plus Fixed Fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Other Lab, Inc., a small business, on March 25, 2016 for $3,947,198.00. The contract is for a "BTO STUDY - COMPLIANT MATERIAL SIMULATION AND DEVELOPMENT ENVIRONMENT" related to DARPA's Biological Technologies Office (BTO) and was awarded under DARPA-BAA-15-35. The contract has an ultimate completion date of March 29, 2019 and does not have a set-aside designation. Other Lab,...
- This is a $2,177,827.00 cost-plus-fixed-fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to RTX BBN Technologies, Inc., doing business as BBN Technologies. The contract is for a "TOOL-CHAIN TO ACCELERATE SYNTHETIC BIOLOGICAL ENGINEERING PROTOTYPE SOFTWARE" and does not have a set-aside designation. BBN Technologies is a research and engineering services provider specializing in advanced technology development for the U.S. government. As a subsidiary of...
- The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) awarded a $14,951,374.29 cost-plus-fixed-fee Delivery Order contract to Booz Allen Hamilton Inc. for molecular biology and biosecurity technical and administrative support services. This award is under the DARPA BTO SETA Support Services (BTO SETA) Indefinite Delivery Vehicle. The contract is for work performed in Arlington, Virginia and does not have a set-aside designation. Booz Allen Hamilton Inc. is...
- The Defense Advanced Research Projects Agency (DARPA) awarded a $999,855.00 Other Transaction Agreement contract to Leaflabs, LLC for the development of the WILD:CARROT (WASP INSPIRED LOGIC DEVICE: CONNECTOME AND RNA PROFILES REPRESENTED ON TRANSISTORS) project. The contract is not associated with a set-aside and has an end date of October 2, 2020. The project aims to leverage wasp-inspired logic devices and connectome/RNA profiles to create novel transistor-based technologies. As DARPA's...
- This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also...
The Defense Advanced Research Projects Agency (DARPA) awarded an Other Transaction Agreement to Ansa Biotechnologies, Inc. valued at $392,516 on November 14, 2025, for the BTO Seedling project titled "De-Risking a Novel Error Correction Technique for Genome-Scale DNA Synthesis." The contract, which carries no set-aside designation, is scheduled for completion by March 13, 2026, with work to be performed at the contractor's Oakland, California facility. This award falls under DARPA's Biological Technologies Office (BTO), which focuses on leveraging biological systems and processes for defense applications. The seedling-phase effort aims to advance and validate an innovative error correction methodology applicable to large-scale DNA synthesis, a critical capability for synthetic biology and biodefense applications. By de-risking this novel technique during the seedling phase, the project will establish technical feasibility and reduce technological uncertainties, potentially enabling future larger-scale development efforts. The relatively short performance period and modest contract value are characteristic of DARPA seedling awards, which are designed to explore early-stage, high-risk concepts with the potential for significant impact on defense biotechnology capabilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $392.5k | 11/14/25 |